Key points:
- OCGN stock tanked 23% premarket on FDA disapproval of Covaxin EAU
- Once trading at $600, OCGN now can be snapped up for just above $3
- After last weeks 50% surge, Ocugen may still be a good play on the continued vaccine race
Today, Ocugen (NASDAQ: OCGN) stock tanked over 23% premarket on news that the FDA has declined to issue an Emergency Use Authorization (EUA) for the pediatric use of Covaxin in the fight against Covid-19.
The stock dips comes shortly after last week’s price surge; which saw a 50% rise in OCGN stock after the FDA moved to lift its clinical hold on Covaxin. Ocugen – amongst other vaccine manufacturers – have been prone to extreme bouts of market volatility throughout the length of the pandemic, normally attested to approvals or disapprovals from the FDA.
The fight against Covid isn’t quite over. Drug manufacturers are still working tirelessly on ensuring more than one efficient and stable vaccine is commonly available. The ‘multiple vaccine’ approach isn’t just necessary for a complete recovery, but it’s also a golden gate into a variety of approachable investment opportunities.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ocugen, for example, has lost almost 100% of its stock value since the company began public trading in 2015, where it briefly traded around peaks of $640. Today, Ocugen stock can be snapped up for a mere $3.29. For a company that is teetering on the edge of another promising Covid vaccine, it’s a stock certainly worth looking at it.
In terms of Covaxin, the company has stated that it “intends to continue working with FDA to evaluate the regulatory pathway for the pediatric use of COVAXIN.” Should Ocugen reach the required pathways needed in the near future, there is little reason as to why OCGN stock can’t bounce with a repeat of last week’s 50% gain or more.
